<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200622047887N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-06</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the anesthetic efficacy of Articaine infiltration versus Lidocaine inferior alveolar nerve block in children pulpotomy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the anesthetic efficacy of 4% Articaine infiltration versus 2% Lidocaine inferior alveolar nerve block in pulp therapy of mandibular primary second molars in  5-8 years old children</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-07-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/49157</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: We use block randomization with size of 10 to randomize treatment for the patients.
According to the comparison of the two types of anesthetics, at first, the subjects were divided into two groups, A and B, based on which treatment they received in the first session.in each block of 10, 5 people randomly receive A treatment and 5 people receive B treatment. Randomization was performed using version 9 of SAS software.Based on this, considering that the sample size is 40, we had 4 blocks of 10.
In order to randomly assign the treatment to the patients right or left, a 10-shift permutation randomization was used again, considering that we indicated the right and left with letters C and D. in the previous randomization, we specified which anesthesia each person would receive. in this randomization, we specified which direction the anesthesia would be injected. based on this, we had random blocks of 10 that identified 5 on the right and 5 on the left, Blinding description: All injections will be performed by a pediatric dentist who is not aware of anesthetic drug type and study method.Dentist will receive anesthetic drugs in the same boxes without name and will be marked as A and B. In this way, dentist and patient will not be aware of treatment type.</study_design>
      <phase>3</phase>
      <hc_freetext>Anesthesia in pediatric pulpotomy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group patients will receive 1.8 ml Articaine 4% infiltration injection in mandibular primary second molar and their tooth anesthesia during the pulp therapy will be evaluated. Tehran Daru Pakhsh will provide the drug. Intervention 2: Control group: In this group patients will receive 1.8 ml Lidocaine 2% Inferior alveolar nerve block injection and their anesthesia during the pulp therapy of mandibular primary second molar will be evaluated. Tehran Daru Pakhsh will provide the drug.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Data are shareable after making them unidentifiable

When:
accessibility starts from 6 month after being published

To whom:
The  data will be available to researchers working in academic and scientific institutions

Conditions:
Researchers can use them by citing references.

Where to obtain:
Dr. seyed hedyeh daneshvar
dr.daneshvar@gums.ac.ir

How to obtain:
There is no special process.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Seyed Hedyeh Daneshvar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dentistry faculty, Guilan medical sciences complex, Fuman_Saravan Highway</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>41941-73774</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>dr.daneshvar@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Seyed Hedyeh Daneshvar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dentistry faculty, guilan medical sciences complex,  Fuman_Saravan Highway</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>41941-73774</zip>
        <telephone>+98 13 3348 6406</telephone>
        <email>dr.daneshvar@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>5-8 years healthy children who require pulp therapy of mandibular primary second molar in both sides
appropriate cooperation of child for dental treatment under local anesthesia(class of 3 or 4 Frunkle scale)
parents' consent for study entrance</inclusion_criteria>
      <agemin>5 years</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Presence of any inflammation or infection of soft tissue near the injection area
Presence of any Allergic reaction to anesthetic soluble
Children communication problem with others
Presence of a systemic problems that interferes with the use of epinephrine containing anesthetics
Using any drug within last 24 hours which interfere with pain evaluation
presence of any systemic diseases and mental disorders
patients with hypermic primary second molars which require pulpectomy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group patients will receive 1.8 ml Articaine 4% infiltration injection in mandibular primary second molar and their tooth anesthesia during the pulp therapy will be evaluated. Tehran Daru Pakhsh will provide the drug.</i_keyword>
      <i_keyword>Control group: In this group patients will receive 1.8 ml Lidocaine 2% Inferior alveolar nerve block injection and their anesthesia during the pulp therapy of mandibular primary second molar will be evaluated. Tehran Daru Pakhsh will provide the drug.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Facial Image Scale(FIS). Timepoint: Immediately after pulp exposure. Method of measurement: facial image scale graph.</prim_outcome>
      <prim_outcome>Sound , Eye &amp; Motor scale  (SEM). Timepoint: Immediately after pulp exposure. Method of measurement: patient behavior objective evaluation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-07-29</approval_date>
        <contact_name>Ethics Committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Deputy of Research and Technology, In front of 17 Sharivar Hospital, Shahid Siadati Ave., Namjo Ave. Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
